For biopharmaceutical injectable drug delivery
BD Medical, a division of BD (Becton, Dickinson and Company), a global medical technology company headquartered in the US, has launched the BD Neopak, a new glass prefillable syringe system engineered for the administration of biopharmaceutical injectable drugs.
The company says the product addresses industry challenges in developing, manufacturing and marketing biologic drugs to patients.
The BD Neopak is manufactured in a fully indexed process, which eliminates glass-to-glass contact resulting in fewer visual defects and increased glass strength. The new process reduces silicone levels while maintaining the appropriate glide force functionality. Through tighter dimensional tolerances and by limiting the dead volume space, the BD Neopak also reduces waste and overfilling of the biologic drug, the firm says.
‘In today's environment, regulatory authorities, patients and prescribers demand higher quality and more reliability in injectable drug delivery systems,’ said Claude Dartiguelongue, President, BD Medical – Pharmaceutical Systems.
‘The BD Neopak Glass Prefillable Syringe is designed to reduce risks associated with primary container and drug interactions and enable our customers' drug products speed to market safely and effectively.’